Psychological Well-Being: Clinical Trials

13 trials for Psychological Well-Being, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 recruiting, 1 terminated, 1 unknown. 13 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 413Completed 10, Recruiting 1, Terminated 1, Unknown 1

Follow Psychological Well-Being: new trials by email Literature Review of Psychological Well-Being trials Research Report on Psychological Well-Being

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
Esketamine hydrochloride (intranasal), Integration Therapy - Treatment-resistant Depression (TRD)
Phase 4RecruitingUniversity of Puerto Rico202026-02-012026-01-27
The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment
Cannabidiol Oil, Homotaurine - Mild Cognitive Impairment
Phase 4UnknownAristotle University Of Thessaloniki902021-04-012021-08-26
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Ketamine-Assisted Psychotherapy (KAP) - Depression, Anxiety
Phase 4CompletedField Trip Health18062020-03-132024-03-20
Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression
Escitalopram, Bupropion - Depression
Phase 4TerminatedUniversity of Texas Southwestern Medical Center182019-07-232023-04-18
Optimum Thiamine Intervention (OpTIn) Trial
Thiamine Hydrochloride - Wernicke-Korsakoff Syndrome
Phase 4CompletedMenzies School of Health Research3342014-09-012019-08-16
The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff
Vitamin D3, Placebo - Seasonal Affective Disorder, Vitamin D3
Phase 4CompletedConnie Thuree Nielsen, consultant, MD, ph.d502011-10-012012-03-29
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
Selegiline Transdermal System, Placebo - Major Depressive Disorder
Phase 4CompletedSomerset Pharmaceuticals3082007-07-012014-01-15
Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults
donepezil, Placebo (cornstarch) - Mental Health, Geriatrics
Phase 4CompletedSunnybrook Health Sciences Centre222007-06-012019-05-10
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
Provigil - Major Depression, Mental Health
Phase 4CompletedEmory University1002003-02-012013-11-11
Effectiveness of Screening and Counselling for Elderly With Psychological Problems
Brief counselling, Behavior - Mental Illness
Phase 4CompletedThe University of Hong Kong4502002-11-012006-01-27
Study To Evaluate The Effects Of Gabitrilâ„¢ In Patients With Social Anxiety Disorder
Gabitril - Social Anxiety Disorder
Phase 4CompletedEmory University502002-06-012013-11-11
Psychological Well-being, Recovery and Sexuality After Total and Subtotal Hysterectomy
Total abdominal hysterectomy, Subtotal abdominal hysterectomy - Hysterectomy
Phase 4CompletedUniversity Hospital, Linkoeping2001998-03-012012-06-11
Thyroid Medication and Antidepressants for Treating Major Depression
Triiodothyronine, Placebo, Sertraline - Major Depression
Phase 4CompletedEmory University1531996-09-012015-11-17

Narrower conditions

Depression (6)  ·  Depressive Disorder, Major (4)  ·  Anxiety Disorders (1)  ·  Cognitive Dysfunction (1)  ·  Depressive Disorder, Treatment-Resistant (1)  ·  Dissociative Disorders (1)  ·  Korsakoff Syndrome (1)  ·  Mental Disorders (1)  ·  Mood Disorders (1)  ·  Neurologic Manifestations (1)  ·  Phobia, Social (1)  ·  Seasonal Affective Disorder (1)  ·  Stress Disorders, Post-Traumatic (1)

Broader conditions

Behavior (13)  ·  Personal Satisfaction (13)  ·  Mental Disorders (9)  ·  Behavioral Symptoms (6)  ·  Depressive Disorder (6)  ·  Mood Disorders (5)  ·  Anxiety Disorders (1)  ·  Cognition Disorders (1)  ·  Memory Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurocognitive Disorders (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Phobic Disorders (1)  ·  Signs and Symptoms (1)

Interventions

5''-hydroxycannabidiol glucoside (1)  ·  Bupropion (1)  ·  Cannabidiol (1)  ·  Cholecalciferol (1)  ·  Donepezil (1)  ·  Escitalopram (1)  ·  Esketamine (1)  ·  Exercise (1)  ·  Modafinil (1)  ·  Selegiline (1)  ·  Sertraline (1)  ·  Starch (1)  ·  Thiamine (1)  ·  Tiagabine (1)  ·  Triiodothyronine (1)

Sponsors

Emory University (3)  ·  Aristotle University Of Thessaloniki (1)  ·  Connie Thuree Nielsen, consultant, MD, ph.d (1)  ·  Field Trip Health (1)  ·  Menzies School of Health Research (1)  ·  Somerset Pharmaceuticals (1)  ·  Sunnybrook Health Sciences Centre (1)  ·  The University of Hong Kong (1)  ·  University Hospital, Linkoeping (1)  ·  University of Puerto Rico (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (6)  ·  Canada (2)  ·  Australia (1)  ·  Denmark (1)  ·  Greece (1)  ·  Puerto Rico (1)  ·  Sweden (1)

Top investigators

Philip T Ninan, MD (2)  ·  Boadie W Dunlop, MD, MS (1)  ·  Chris Lo, PhD (1)  ·  Cindy L Lam, MD (1)  ·  Karen G Gonzalez-Martinez, MD, MSc (1)  ·  Krista Lanctot, PhD (1)  ·  Kylie Dingwall, PhD (1)  ·  Madhukar H Trivedi, MD (1)  ·  Mark Rapoport, MD, FRCPC (1)  ·  Melissa L Goodhead (1)  ·  Michel Bedard, PhD (1)  ·  Nathan Herrmann, MD, FRCPC (1)  ·  Ryan Yermus, MD (1)

Results publications

PMID 22964160, PMID 25125215, PMID 41938228

NIH funding

R01MH056946 (1)